Thyroid dysfunction associated with iodine-contrast media: A real-world pharmacovigilance study based on the FDA adverse event reporting system

Lu Huang; Yan Luo; Zhen-Lin Chen; Zhi-Yun Yang; Yue Wu

doi:10.1016/j.heliyon.2023.e21694

Thyroid dysfunction associated with iodine-contrast media: A real-world pharmacovigilance study based on the FDA adverse event reporting system

Heliyon. 2023 Oct 26;9(11):e21694. doi: 10.1016/j.heliyon.2023.e21694. eCollection 2023 Nov.

Authors

Lu Huang^{1

2

3}, Yan Luo^{1

2

4}, Zhen-Lin Chen³, Zhi-Yun Yang^{5

6}, Yue Wu^{1

2}

Affiliations

¹ Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
² Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
³ Department of Pharmacy, People's Hospital of Fushun County, Fushun, China.
⁴ Department of Pharmacy, Chengdu Seventh People's Hospital, Chengdu, China.
⁵ Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
⁶ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Institute for Rational and Safe Medication Practices, Central South University, Changsha, China.

Abstract

Objective: To comprehensively analyze characteristics of thyroid dysfunction associated with iodine contrast media (ICM) based on data from the FDA adverse event reporting system (FAERS).

Methods: Disproportionate analysis was employed to identify signals of thyroid dysfunction caused by ICM, and descriptive analysis was performed to examine the clinical characteristics of reported cases involving ICM-related thyroid dysfunctions.

Results: A total of 83 adverse event reports were identified, documenting thyroid dysfunctions associated with ICM agents. Treatment with ICM was significantly associated with higher reporting of hypothyroidism ([ROR] = 2.21, 95 % CI: 1.59-3.08; IC₀₂₅ = 0.58) and hyperthyroidism (ROR = 3.49, 95 % CI: 2.37-5.13; IC₀₂₅ = 1.14). Among the six ICM agents investigated, iodixanol demonstrated the highest signal strength in both hypothyroidism (ROR = 9.47) and hyperthyroidism (ROR = 5.44). Hypothyroidism and hyperthyroidism almost occurred in the first 30 days after ICM administration (76.9 % and 70 % of patients, respectively). Furthermore, the proportion of severe outcomes in hyperthyroidism was significantly higher than that in hypothyroidism (12/26 vs. 2/35, P = 0.009).

Conclusion: The present study highlights the varying risks of thyroid dysfunction associated with different ICM agents, with iodixanol exhibiting the highest signal intensity. Hypothyroidism and hyperthyroidism associated with ICM generally manifest within the first month following administration. Consequently, monitoring of thyroid function during this period is strongly recommended for ICM agents presenting higher risk profiles.